Product Name :
LM11A-31 HCl
Description:
LM11A-31 is a small-molecule p75NTR modulator and proNGF antagonist, in preventing diabetes-induced BRB breakdown. Targeting p75NTR signalling using LM11A-31, an orally bioavailable receptor modulator, may offer an effective, safe and non-invasive therapeutic strategy for treating macular oedema, a major cause of blindness in diabetes.
CAS:
1243259-19-9
Molecular Weight:
316.27
Formula:
C12H27Cl2N3O2
Chemical Name:
(2S,3S)-2-amino-3-methyl-N-[2-(4-morpholinyl)ethyl]-pentanamide, dihydrochloride
Smiles :
Cl.Cl.C[C@@H](CC)[C@H](N)C(=O)NCCN1CCOCC1
InChiKey:
LLIHJRRZJDEKLB-ULEGLUPFSA-N
InChi :
InChI=1S/C12H25N3O2.{{4β-Hydroxycholesterol-d7} MedChemExpress|{4β-Hydroxycholesterol-d7} Endogenous Metabolite|{4β-Hydroxycholesterol-d7} NF-κB|{4β-Hydroxycholesterol-d7} Protocol|{4β-Hydroxycholesterol-d7} Formula|{4β-Hydroxycholesterol-d7} custom synthesis} 2ClH/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15;;/h10-11H,3-9,13H2,1-2H3,(H,14,16);2*1H/t10-,11-;;/m0../s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
LM11A-31 is a small-molecule p75NTR modulator and proNGF antagonist, in preventing diabetes-induced BRB breakdown. Targeting p75NTR signalling using LM11A-31, an orally bioavailable receptor modulator, may offer an effective, safe and non-invasive therapeutic strategy for treating macular oedema, a major cause of blindness in diabetes.|Product information|CAS Number: 1243259-19-9|Molecular Weight: 316.27|Formula: C12H27Cl2N3O2|Synonym:|LM11A-31 hydrochloride|LM11A-31|LM-11A-31|LM11A-31 HCl|LM11A 31|LM11A31|LM 11A-31|LM 11A31|Chemical Name: (2S,3S)-2-amino-3-methyl-N-[2-(4-morpholinyl)ethyl]-pentanamide, dihydrochloride|Smiles: Cl.Cl.C[C@@H](CC)[C@H](N)C(=O)NCCN1CCOCC1|InChiKey: LLIHJRRZJDEKLB-ULEGLUPFSA-N|InChi: InChI=1S/C12H25N3O2.2ClH/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15;;/h10-11H,3-9,13H2,1-2H3,(H,14,16);2*1H/t10-,11-;;/m0../s1|Technical Data|Appearance: Solid Power.{{Linperlisib} site|{Linperlisib} PI3K|{Linperlisib} Purity & Documentation|{Linperlisib} Purity|{Linperlisib} manufacturer|{Linperlisib} Epigenetic Reader Domain} |Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:25955218 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vivo:|LM11A-31 (oral gavage; 50 mg kg/day for 4 weeks) significantly mitigates proNGF accumulation and preserves BRB integrity. LM11A-31 (orally; 50 or 75 mg/kg) administered for 3 months starting at 6-8 months of age prevents and/or reverses atrophy of basal forebrain cholinergic neurites and cortical dystrophic neurites in mid-stage male APPL/S mice.|References:|McGregor C, Sabatier M, English A. Early regeneration of axons following peripheral nerve injury is enhanced if p75NTR is eliminated from the surrounding pathway. Eur J Neurosci. 2020 Aug 19. doi: 10.1111/ejn.14943. Epub ahead of print. PMID: 32812660.Xie Y, Seawell J, Boesch E, Allen L, Suchy A, Longo FM, Meeker RB. Small molecule modulation of the p75 neurotrophin receptor suppresses age- and genotype-associated neurodegeneration in HIV gp120 transgenic mice. Exp Neurol. 2020 Sep 29;335:113489. doi: 10.1016/j.expneurol.2020.113489. Epub ahead of print. PMID: 33007293.Products are for research use only. Not for human use.|
